Cost-Effectiveness Analysis of a Prescription Digital Therapeutic in Type 2 Diabetes.
Niall J DavisonNicole L GuthrieSarah MedlandPaul LupinacciRobert J NordykeMark A BermanPublished in: Advances in therapy (2024)
BT-001 plus SoC was estimated to dominate SoC alone over the lifetime horizon from a payer perspective, suggesting that using BT-001 can empower patients to better manage their diabetes with the potential for lifelong advantages.